Maciej M Mrugala

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 6

Top Topics

African American

Chronic Kidney Disease

Juvenile Idiopathic Arthritis

Top Venues

Current treatment options in oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Shannon P Fortin Ensign, Charles Gaulin, Maya Hrachova, Michael Ruff, Ehab Harahsheh, Kevin Vicenti, Januario Castro, Javier Munoz, Allison Rosenthal, Maciej M Mrugala
Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy. Current treatment options in oncology 23 (12) (2022)
Shannon P Fortin Ensign, Diamone Gathers, Julia Erin Wiedmeier, Maciej M Mrugala
Central Nervous System Lymphoma: Novel Therapies. Current treatment options in oncology 23 (1) (2022)
Shannon P Fortin Ensign, Charles Gaulin, Maya Hrachova, Michael Ruff, Ehab Harahsheh, Kevin Vicenti, Januario Castro, Javier Munoz, Allison Rosenthal, Maciej M Mrugala
Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy. Current treatment options in oncology 23 (12) (2022)
Shannon P Fortin Ensign, Charles Gaulin, Maya Hrachova, Michael Ruff, Ehab Harahsheh, Kevin Vicenti, Januario Castro, Javier Munoz, Allison Rosenthal, Maciej M Mrugala
Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy. Current treatment options in oncology (2022)
Shannon P Fortin Ensign, Charles Gaulin, Maya Hrachova, Michael Ruff, Ehab Harahsheh, Kevin Vicenti, Januario Castro, Javier Munoz, Allison Rosenthal, Maciej M Mrugala
Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy. Current treatment options in oncology 23 (12) (2022)
Shannon P Fortin Ensign, Charles Gaulin, Maya Hrachova, Michael Ruff, Ehab Harahsheh, Kevin Vicenti, Januario Castro, Javier Munoz, Allison Rosenthal, Maciej M Mrugala
Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy. Current treatment options in oncology 23 (12) (2022)